Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction

• Published in: The New England journal of medicine Vol. 344; no. 18; pp. 1351 - 1357
• Main Authors: Exner, Derek V, Dries, Daniel L, Domanski, Michael J, Cohn, Jay N
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 03.05.2001
• Subjects: Adult; African Continental Ancestry Group; Aged; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive agents; Biological and medical sciences; Black people; Cardiovascular disease; Cardiovascular system; Cohort Studies; Comparative analysis; Drug therapy; Enalapril - therapeutic use; Enzymes; European Continental Ancestry Group; Female; Heart Failure - drug therapy; Heart Failure - ethnology; Heart Failure - prevention & control; Hospitalization - statistics & numerical data; Humans; Male; Medical sciences; Middle Aged; Mortality; Patients; Pharmacology. Drug treatments; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left - drug therapy; Ventricular Dysfunction, Left - ethnology; Ventricular Dysfunction, Left - prevention & control; White people; Human; Hypertension; Heart failure; Mortality; Negroid; Cardiovascular disease; Heart ventricle; Left ventricular failure; Prevention; Chemotherapy; Randomization; Treatment; Enalapril; Heart disease; Race; Complication; Clinical trial; Caucasoid; Comparative study
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM200105033441802

Large-scale trials of therapy for heart failure over the past decade have shown improvements in outcome with angiotensin-converting–enzyme (ACE) inhibitors and beta-blockers. 1 – 7 In the Studies of Left Ventricular Dysfunction (SOLVD), two concurrent trials evaluating the efficacy of enalapril in patients with left ventricular systolic dysfunction, enalapril was associated with a 16 percent reduction in the risk of death from any cause among patients with symptoms 6 and a 20 percent reduction in the risk of death from any cause or hospitalization for heart failure among patients without symptoms. 7 These results and the results of other studies 1 – 5 led to the . . .